Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner
- PMID: 12558562
- DOI: 10.1046/j.1563-2571.2003.02045.x
Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner
Abstract
Today, positron emission tomography (PET) investigation using fluorodeoxyglucose (FDG) is the most sensitive and specific single modality established for localizing metastases of medullary thyroid cancer (MTC). Even at calcitonin serum levels below 20 pg/ml, tumour localization may be successful in individual cases. However, especially in such early tumour stages, the morphological correlation using PET is unsatisfactory. With the newly available fixed combination of PET and computed tomography (PET/CT), this drawback can be overcome as PET/CT allows a point-by-point correlation of pathological function with morphological structure. Conventional PET alone yielded an approx 80 % sensitivity and specificity in MTC: a result that will be surpassed by the combined PET/CT scanner.
Similar articles
-
Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.Endokrynol Pol. 2006 Jul-Aug;57(4):452-5. Endokrynol Pol. 2006. PMID: 17006852
-
Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.Ann Surg Oncol. 2004 Aug;11(8):786-94. doi: 10.1245/ASO.2004.10.015. Ann Surg Oncol. 2004. PMID: 15289241
-
The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.Eur J Nucl Med. 2000 May;27(5):490-6. doi: 10.1007/s002590050533. Eur J Nucl Med. 2000. PMID: 10853802 Clinical Trial.
-
Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer.Biomed Pharmacother. 2006 Sep;60(8):409-13. doi: 10.1016/j.biopha.2006.07.008. Epub 2006 Aug 1. Biomed Pharmacother. 2006. PMID: 16891093 Review.
-
18F-DOPA and 18F-FDG PET/CT, scintigraphic localization and radioguided surgery of recurrent medullary thyroid cancer: two case reports.Curr Radiopharm. 2014;7(2):133-7. doi: 10.2174/1874471007666141027151130. Curr Radiopharm. 2014. PMID: 25355429 Review.
Cited by
-
Correlation between Calcitonin Levels and [(18)F]FDG-PET/CT in the Detection of Recurrence in Patients with Sporadic and Hereditary Medullary Thyroid Cancer.ISRN Endocrinol. 2012;2012:375231. doi: 10.5402/2012/375231. Epub 2012 May 10. ISRN Endocrinol. 2012. PMID: 22655204 Free PMC article.
-
The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers.Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1674-83. doi: 10.1007/s00259-003-1300-4. Epub 2003 Aug 21. Eur J Nucl Med Mol Imaging. 2003. PMID: 12937950 Clinical Trial.
-
[Whole-body tumor staging: MRI or FDG-PET/CT?].Radiologe. 2004 Sep;44(9):882-8. doi: 10.1007/s00117-004-1093-x. Radiologe. 2004. PMID: 15349729 Review. German.
-
The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.Eur Radiol. 2009 Jun;19(6):1425-34. doi: 10.1007/s00330-008-1280-7. Epub 2009 Jan 21. Eur Radiol. 2009. PMID: 19156423
-
Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT.Mol Imaging Biol. 2007 Mar-Apr;9(2):72-7. doi: 10.1007/s11307-006-0072-1. Mol Imaging Biol. 2007. PMID: 17186139
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical